ArticleBreast cancer research and treatment2026
Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Primary G-CSF prophylaxis in sacituzumab govitecan-treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Toxicities of Antibody-Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeSevere neutropenia (SN) and febrile neutropenia (FN) are clinically significant safety concerns of sacituzumab govitecan-hziy (SG). We sought to compare the rates of SN and FN from clinical trials to real-world experience, correlate factors with SN and FN, and quantify granulocyte colony-stimulating factor (G-CSF) use in HER2-negative (HER2-) metastatic breast cancer (mBC).
methodsWe performed a retrospective analysis of patients treated with SG for advanced HER2- BC at a single US institution with a diverse patient population. The rates of SN and FN, stratified by receptor status, were compared to their respective phase III clinical trials. Multivariable logistic regression was used to evaluate factors associated with SN and FN.
resultsOf 87 patients treated with SG, 10 patients received primary prophylaxis. Of the 77 patients who didn't receive primary G-CSF prophylaxis, 49% and 3.9% patients developed SN and FN, respectively. SN and FN rates did not differ in the HR + /HER- mBC or mTNBC subgroups compared to clinical trials. Factors evaluated in this study were not shown to be associated with SN. Overall, 44% (38/87) required a dose interruption or reduction due to SN or FN. 11% (10/87) and 60% (52/87) received G-CSF as primary and secondary prophylaxis respectively, with a total G-CSF drug cost of $2.1 million.
conclusionsSG-induced SN and FN rates were similar to those reported in clinical trials, both in the HR + /HER- mBC and mTNBC groups. Due to small sample size, we did not identify any statistically significant risk factors of SG-associated SN. Our study provided insights into G-CSF use patterns and costs in real-world SG therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.